

Table S4. Percentage of hyper Vif derivatives in intermediate A3H humanized mice co-inoculated with hyper and hypo HIV-1s.

Mouse no.*	Donor lot*	<i>APOBE3H</i> haplotype		# Analyzed sequence	# Hyper Vif derivatives	% Hyper Vif derivatives	#Hypo Vif derivatives	% Hypo Vif derivatives	# Hypo Vif derivatives with anti-A3H activity	% Vif with anti-A3H-II activity†
9	C	I/I	Intermediate	33	2	6.1	31	93.9	0	6.1
10	C	I/I	Intermediate	47	18	38.3	29	61.7	0	38.3
11	C	I/I	Intermediate	49	14	28.6	35	71.4	0	28.6
12	C	I/I	Intermediate	47	13	27.7	34	72.3	0	27.7
13	D	I/VI	Intermediate	50	33	66.0	17	34.0	0	66.0
14	E	I/I	Intermediate	47	47	100.0	0	0.0	0	100.0
Average				273	127	46.5	146	53.5		46.5
SEM						13.7		13.7		13.7

* Identical to Figure 2 and Table S1.

† Percentage of hyper Vif derivatives and the hypo Vif derivatives acquiring anti-A3H-II activity.